Condition
Advanced Hepatocellular Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownMorning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT StudyNCT07405086 · 2026-06-08
RECRUITINGAblation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular CarcinomaNCT06644430 · 2024-10-04
RECRUITINGAt-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced CancerNCT05969860 · 2023-08-23
RECRUITINGPhase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxNCT05092373 · 2022-04-29
RECRUITINGA Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCCNCT05773105 · 2023-09-19
COMPLETEDTesting the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNCT04514484 · 2021-11-22
ACTIVE_NOT_RECRUITINGSafety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)NCT04740307 · 2021-03-16
COMPLETEDCommon interventions
Biospecimen CollectionPROCEDURE2Cabozantinib S-malateDRUG2AblationPROCEDURE1AtezolizumabBIOLOGICAL1Cadonilimab+regorafenibDRUG1Clinical EncounterPROCEDURE1Computed TomographyPROCEDURE1Home Health EncounterOTHER1Immune Checkpoint InhibitorDRUG1LenvatinibDRUG1Magnetic Resonance ImagingPROCEDURE1Nab-paclitaxelDRUG1NivolumabBIOLOGICAL1PembrolizumabBIOLOGICAL1Pembrolizumab/QuavonlimabBIOLOGICAL1Quality-of-Life AssessmentOTHER1Questionnaire AdministrationOTHER1system therapyDRUG1Tumor Treating Fields TherapyPROCEDURE1
Leading sponsors
Trial status mix
RECRUITING4
COMPLETED2
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE13
PHASE23
PHASE41
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.